3-溴-2-氯吡啶-5-磺酰氯 | 216394-05-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-溴-2-氯吡啶-5-磺酰氯
• 中文别名: 2-氯-3-溴吡啶-5-磺酰氯；5-溴-6-氯吡啶-3-磺酰氯
• 英文名称: 5-bromo-6-chloropyridine-3-sulfonyl chloride
• 英文别名: 3-bromo-2-chloropyridine-5-sulfonyl chloride；5-bromo-6-chloro-3-pyridinesulfonyl chloride；pyridine-3-bromo-2-chloro-5-sulphonyl chloride
• CAS: 216394-05-7
• 化学式: C₅H₂BrCl₂NO₂S
• mdl: MFCD01318107
• 分子量: 290.952
• InChiKey: TURGMVYIESHZBE-UHFFFAOYSA-N

物化性质

• 熔点：
  71-73°C
• 沸点：
  352.8±42.0 °C(Predicted)
• 密度：
  1.973±0.06 g/cm3(Predicted)
• 溶解度：
  溶于二氯甲烷
• 稳定性/保质期：
  避免氧化物、水分和碱性物质。

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R34
• 海关编码：
  2933399090
• 包装等级：
  III
• 危险类别：
  8
• 危险品运输编号：
  3261
• 危险性防范说明：
  P303+P361+P353,P210,P402+P404,P501,P260,P301+P330+P331,P305+P351+P338
• 危险性描述：
  H302,H314
• 储存条件：
  保存方法：密封于阴凉、通风干燥处。

上下游信息

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  5-溴-6-氯吡啶-3-磺酰胺	5-bromo-6-chloropyridine-3-sulfonamide	622815-58-1	C5H4BrClN2O2S	271.522
  3-溴-2-氯-5-甲基磺酰基吡啶	3-bromo-2-chloro-5-methylsulfonylpyridine	1001076-86-3	C6H5BrClNO2S	270.534
  ——	5-bromo-6-chloro-N-methylpyridine-3-sulfonamide	——	C6H6BrClN2O2S	285.549
  ——	3-bromo-2-chloro-5-(ethylsulfonyl)pyridine	1227384-85-1	C7H7BrClNO2S	284.561
  ——	5-bromo-6-chloro-N,N-dimethylpyridine-3-sulfonamide	622815-52-5	C7H8BrClN2O2S	299.576
  ——	5-bromo-6-chloro-N-prop-2-enylpyridine-3-sulfonamide	622815-22-9	C8H8BrClN2O2S	311.587
  ——	5-bromo-N-tert-butyl-6-chloropyridine-3-sulfonamide	——	C9H12BrClN2O2S	327.629
  ——	5-bromo-6-chloro-N-(oxetan-3-yl)pyridine-3-sulfonamide	1604062-17-0	C8H8BrClN2O3S	327.586
  ——	5-bromo-6-chloro-N,N-diethylpyridine-3-sulfonamide	622815-46-7	C9H12BrClN2O2S	327.629

反应信息

• 作为反应物：
  描述：

  3-溴-2-氯吡啶-5-磺酰氯 在 四(三苯基膦)钯 、 双(三甲基硅烷基)氨基钾 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 130.0 ℃ 、1.38 MPa 条件下， 反应 63.0h， 生成 5-[2-乙氧基-5-(4-乙基哌嗪-1-基磺酰基)吡啶-3-基]-3-乙基-2-(2-甲氧基乙基)-2,6-二氢-7H-吡唑并[4,3-D]嘧啶-7-酮
  参考文献：
  名称：

  The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics

  摘要：

  This paper describes our recent efforts to design and synthesise potent and selective PDE5 inhibitors and the use of in vitro predictors of clearance, absorption and permeability to maximise the potential for dose-proportional pharmacokinetics and good oral bioavailability in man. Optimisation of the preclinical profile resulted in the identification of UK-369003 (19a) and its nomination as a clinical candidate. The clinical pharmacokinetic and safety profile has enabled us to progress the compound to test its efficacy in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and a paper describing its efficacy has recently been published. 2,3 (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.10.022
• 作为产物：
  描述：

  2-氨基吡啶 在 盐酸 、 硫酸 、 三氧化硫 、 溴 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 9.5h， 生成 3-溴-2-氯吡啶-5-磺酰氯
  参考文献：
  名称：

  The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics

  摘要：

  This paper describes our recent efforts to design and synthesise potent and selective PDE5 inhibitors and the use of in vitro predictors of clearance, absorption and permeability to maximise the potential for dose-proportional pharmacokinetics and good oral bioavailability in man. Optimisation of the preclinical profile resulted in the identification of UK-369003 (19a) and its nomination as a clinical candidate. The clinical pharmacokinetic and safety profile has enabled us to progress the compound to test its efficacy in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and a paper describing its efficacy has recently been published. 2,3 (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.10.022

文献信息

• [EN] SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN<br/>[FR] COMPOSÉS DE SULFONYLE QUI INTERAGISSENT AVEC LA PROTÉINE RÉGULATRICE DE LA GLUCOKINASE
  申请人：AMGEN INC

  公开号：WO2013123444A1

  公开（公告）日：2013-08-22

  The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

  本发明涉及与葡萄糖激酶调节蛋白相互作用的磺酰基化合物。此外，本发明涉及使用这些化合物或其药学上可接受的盐治疗2型糖尿病和其他涉及葡萄糖激酶调节蛋白的疾病和/或症状的方法，以及含有这些化合物或其药学上可接受的盐的药物组合物。
• Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction
  申请人：Pfizer Inc.

  公开号：US06407114B1

  公开（公告）日：2002-06-18

  There is provided compounds of formula IA and of formula IB, wherein R1, R2, R3, R4 and A have meanings given in the description, which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.

  提供了式IA和式IB的化合物， 其中R1、R2、R3、R4和A的含义如描述中所示，在治疗和预防需要抑制环状鸟苷3′,5′-单磷酸酯酶（例如cGMP PDE5）的医疗状况中非常有用。
• Sulfonamides having antiangiogenic and anticancer activity
  申请人：——

  公开号：US20040157836A1

  公开（公告）日：2004-08-12

  Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.

  描述了具有蛋氨酸氨基肽酶-2抑制剂（MetAP2）的化合物。还描述了包括这些化合物的药物组合物、使用这些化合物的治疗方法、抑制血管生成的方法以及治疗癌症的方法。
• [EN] AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS<br/>[FR] DÉRIVÉS AMINÉS DE PYRAZINE UTILISABLES EN TANT QU'INHIBITEURS DE LA PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：NOVARTIS AG

  公开号：WO2015162459A1

  公开（公告）日：2015-10-29

  The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.

  本发明提供了一种公式（I）的化合物，该化合物抑制PI 3-激酶γ同工酶的活性，对于治疗由PI 3-激酶γ同工酶激活介导的疾病是有用的。
• Solid dispersions containing an apoptosis-inducing agent
  申请人：AbbVie Inc.

  公开号：US10213433B2

  公开（公告）日：2019-02-26

  A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

  一种促凋亡的固体分散体包括本文所定义的具有本文所述的化学式I的Bcl-2家族蛋白抑制化合物，以基本非晶态形式分散在包括（a）药学上可接受的水溶性聚合物载体和（b）药学上可接受的表面活性剂的固体基质中。制备这种固体分散体的方法包括在合适的溶剂中溶解化合物、聚合物载体和表面活性剂，并去除溶剂以提供包括聚合物载体和表面活性剂并在其中以基本非晶态形式分散有化合物的固体基质。这种固体分散体适用于口服给予需要治疗由一个或多个抗凋亡Bcl-2家族蛋白过度表达所特征的疾病的受试者，例如癌症。